Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMBR | P28336 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3414001 | 0.99 | NMBR (0.45) | NMBRALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3410558 | 0.85 | NMBR (0.48) | NMBRLMNAKMT2ATAS1R3TAS1R1 | |
| SCHEMBL3412557 | 0.79 | NLRP3 (0.46) | NMBRKMT2A | |
| SCHEMBL3414079 | 0.79 | NMBR (0.49) | NMBRALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3409553 | 0.79 | ALDH1A1 (0.47) | NMBRALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3404762 | 0.78 | NMBR (0.49) | NMBR | |
| SCHEMBL3407725 | 0.78 | ALDH1A1 (0.48) | NMBRALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3409925 | 0.76 | KMT2A (0.36) | NMBRALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3408378 | 0.73 | NMBR (0.47) | NMBRLMNAKMT2A | |
| SCHEMBL3412535 | 0.72 | NMBR (0.48) | NMBRLMNAKMT2ATAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200979-B1 | NOVEL DERIVATIVES OF PHENYLUREAS, INHIBITORS OF THE SOAT-1 ENZYME, PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM | GALDERMA RES & DEV (FR) | 2012-12-12 | — | — | EP | claimed |
| US-8283378-B2 | Phenylurea inhibitors of the SOAT-1 enzyme and pharmaceutical/cosmetic compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-10-09 | — | — | US | claimed |
| US-20100222431-A1 | NOVEL PHENYLUREA INHIBITORS OF THE SOAT-1 ENZYME AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-09-02 | — | — | US | claimed |
| EP-2200979-B1 | NOVEL DERIVATIVES OF PHENYLUREAS, INHIBITORS OF THE SOAT-1 ENZYME, PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM | GALDERMA RES & DEV (FR) | 2012-12-12 | — | — | EP | disclosed |
| US-8283378-B2 | Phenylurea inhibitors of the SOAT-1 enzyme and pharmaceutical/cosmetic compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-10-09 | — | — | US | disclosed |
| US-20100222431-A1 | NOVEL PHENYLUREA INHIBITORS OF THE SOAT-1 ENZYME AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222431-A1 | NOVEL PHENYLUREA INHIBITORS OF THE SOAT-1 ENZYME AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF | SOAT1, SOAT2, ACAT2 | NMBR 4779/4885ALDH1A1 58/4885CYP3A4 1754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.